Expression of miRNA-27a in the serum of patients with non-ST elevation acute coronary syndrome who underwent percutaneous coronary intervention

Coronary artery disease (CAD) is a multifactorial disorder. Previously have been identified genes whose polymorphic variants are associated with an increased risk of CAD. Genetic control of the development of CAD at the post-transcriptional level is carried out using step-wise and multicomponent regulation of gene expression with the participation of specific molecules called micro-ribonucleic acids (miRNAs). Currently, many authors consider these molecules, in particular miRNA-27a, as potential sensitive diagnostic markers for acute coronary syndrome (ACS).

Aim. To assess the level of miRNA-27a expression in the serum of patients underwent percutaneous coronary intervention (PCI) after non-ST elevation ACS.

Material and methods. Forty patients with non-ST elevation ACS who underwent coronary artery stenting were examined. The comparison groups consisted of 80 patients with a stable CAD who underwent coronary artery bypass surgery, and 20 patients without clinical signs of CAD operated due to valvular disorders without atherosclerotic lesions. All patients underwent coronary angiography. The expression level of miRNA-27a was determined in serum by real-time polymerase chain reaction.

Results. In patients with non-ST elevation ACS, who underwent PCI, the expression level of miRNA-27a in serum was higher than in patients without atherosclerotic lesions (6,99±1,69 and 3,05±0,89, respectively; p<0,05). Moreover, patients with multivessel coronary lesions (3 or more arteries) had a higher level of miRNA-27a expression in serum than patients with a single or dual vascular lesion (8,00±2,19 and 5,87±2,64, respectively; p<0,05). In patients with non-ST elevation ACS and patients with a stable CAD, the expression level of miRNA-27a was not significantly different (6,99±1,69 and 8,57±3,90, respectively; p>0,05).

Conclusion. High levels of miRNA-27a expression can be considered as a marker of coronary lesion severity in patients with CAD, but not as a marker for ACS.

1. Sarkozy M, Kahan Z, Csont Т, et al. A myriad of roles of miR-25 in health and disease. Oncotarget. 2018;9:21580-612. doi:1018632/oncotarget.24662.

2. Macgregor-Das A, Das S. A microRNA's Journey to the Center of the Mitochondria. American journal of physiology. 2018;315(2):H206-H215. doi: 10.1152/ajpheart.00714.2017

3. Janaszak-Jasiecka A, Siekierzycka A, Bartoszewska S, et al. eNOS expression and NO release during hypoxia is inhibited by miR-200b in human endothelial cells. Angiogenesis. 2018;21(4):711-24. doi:10.1007/s10456-018-9620-y.

4. Lino M, Simoes S, Vilaca A, et al. Modulation of Angiogenic Activity by Light-Activatable miRNA-Loaded Nanocarriers. ACS Nano. 2018. doi:10.1021/acsnano.7b07538. [Epub ahead of print].

5. Tsoporis J, Fazio A, Rizos IK, et al. Increased right atrial appendage apoptosis is associated with differential regulation of candidate MicroRNAs 1 and 133A in patients who developed atrial fibrillation after cardiac surgery. J Mol Cell Cardiol. 2018. doi:101016/j.yjmcc.2018.06.005. [Epub ahead of print].

6. Gacon J, Kabfak-Ziembicka A, A, Stępień E, et al. Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol. 2016;74(3):280-8. doi:10.5603/KP.a2015.0174.

7. Gacon J, Badacz R, A, Stępień E, et al. Diagnostic and prognostic micro-RNAs in ischaemic stroke due to carotid artery stenosis and in acute coronary syndrome: a four-year prospective study. Kardiol Pol. 2018;76(2):362-9. doi:10.5603/KP.a2017.0243.

8. Li S, Fan Q, He S, et al. MicroRNA-21 negatively regulates Treg cells through a TGF-01/ Smad-independent pathway in patients with coronary heart disease. Cell Physiol Biochem. 2015;37(3):866-78. doi:10.1159/000430214.

9. Shvangiradze TA, Bondarenko IZ, Troshina EA, et al. Profile of microRNAs associated with coronary heart disease in patients with type 2 diabetes. Obesity and metabolism. 2016;13(4):34-8. (In Russ.) doi:1014341/OMET2016434-38.

10. Devaux Y, Vausort M, McCann GP, et al. A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS ONE. 2013;8(8):e70644. doi:10.1371/journal.pone.0070644.e70644.

11. Kukreja R, Yin C, Salloum FN, et al. MicroRNAs: New Players in Cardiac Injury and Protection. Mol Pharmacol. 2011 Oct;80(4):558-64. doi:10.1124/mol.111.073528.

12. Alvarez M, Khosroheidari M, Eddy E, et al. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis. 2015;242(2):595-604. doi:10.1016/j.atherosclerosis.2015.08.023.

13. Aranda J, Madrigal-Matute J, Rotllan N, et al. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med. 2013;64:31-9. doi:10.1016/j.freeradbiomed.2013.07.014.

14. Chen W, Yin K, Zhao GJ, et al. The magic and mystery of MicroRNA-27 in atherosclerosis. Atherosclerosis. 2012;222(2):314-23. doi:10.1016/j.atherosclerosis.2012.01.020.

15. Veliceasa D, Biyashev D, Qin G, et al. Therapeutic manipulation of angiogenesis with miR-27b.Vasc Cell. 2015:7:6. doi:10.1186/s13221-015-0031-1.